Supplementary Figure Legends from Wee-1 Kinase Inhibition Overcomes Cisplatin Resistance Associated with High-Risk TP53 Mutations in Head and Neck Cancer through Mitotic Arrest Followed by Senescence

The Wee-1 inhibitor, MK-1775 Synergizes with cisplatin in vitro in established HNSCC cell lines with known TP53 mutational status; Dual phospho-H3 staining and PI flow cytometric analysis (FACS); The synergy between cisplatin and MK-1775 in HNSCC is not mediated by apoptosis.